nattokinase
Description
nattokinase: isolated from the Japanese soybean cheese Natto; MW: 20,000; pI=8.6 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 75310475 |
MeSH ID | M0152203 |
Synonyms (5)
Synonym |
---|
FT-0660373 |
nattokinase |
AKOS026750311 |
HMS3655P06 |
SB19503 |
Research Excerpts
Overview
Nattokinase (NK) is a serine protease with a potent thrombolytic activity that possesses multiple cardiovascular disease (CVD) preventative and treatment activities. It is an extract from a popular Japanese food, natto, which consists of boiled soybeans fermented with bacteria.
Effects
Nattokinase has been reported as an oral health product for the prevention of atherosclerosis. Nattokin enzyme has been expressed using several heterologous expression systems.
Excerpt | Reference | Relevance |
---|---|---|
"Nattokinase has been expressed using several heterologous expression systems." | ( Heterologous expression of nattokinase from B. subtilis natto using Pichia pastoris GS115 and assessment of its thrombolytic activity. Chao, Z; Guangbo, Y; Lixin, M; Min, S; Wei, S; Yaping, W; Zunxi, H, 2021) | 1.64 |
"Nattokinase has been growing in popularity for use as a dietary supplement for the benefit of cardiovascular health." | ( A pilot study on the serum pharmacokinetics of nattokinase in humans following a single, oral, daily dose. Ero, MP; Harvey, NR; Lewis, BH; Mihailovski, T; Ng, CM, ) | 1.11 |
"Nattokinase has been reported as an oral health product for the prevention of atherosclerosis. " | ( Secretory expression of a heterologous nattokinase in Lactococcus lactis. Huan, L; Liang, X; Zhang, L; Zhong, J, 2007) | 2.05 |
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
" Here, we present a safe and efficient protocol for the isolation of MSCs from 3D fibrin gels." | ( A safe and efficient method to retrieve mesenchymal stem cells from three-dimensional fibrin gels. Carrion, B; Janson, IA; Kong, YP; Putnam, AJ, 2014) | 0.4 |
" [Bacifrinase (ΔN24)], at a dose of 2mg/kg, did not show toxicity, adverse pharmacological effects, tissue necrosis or hemorrhagic effect after 72h of its administration in Swiss albino mice." | ( The N-terminal-truncated recombinant fibrin(ogen)olytic serine protease improves its functional property, demonstrates in vivo anticoagulant and plasma defibrinogenation activity as well as pre-clinical safety in rodent model. Bora, B; Chatterjee, A; Gogoi, D; Kurkalang, S; Mukherjee, AK; Ramani, S; Tripathy, D, 2018) | 0.48 |
Pharmacokinetics
This study intended to detect nattokinase directly and immunologically. Little is known regarding the pharmacokinetic and pharmacodynamic properties of this enzyme. The results further suggest that a larger, more extensive, pharmacokinetics study of nattokerase is warranted.
Excerpt | Reference | Relevance |
---|---|---|
" Little is known regarding the pharmacokinetic and pharmacodynamic properties of this enzyme, and the bioavailability of nattokinase is currently unknown." | ( A pilot study on the serum pharmacokinetics of nattokinase in humans following a single, oral, daily dose. Ero, MP; Harvey, NR; Lewis, BH; Mihailovski, T; Ng, CM, ) | 0.6 |
"This study intended to (1) detect nattokinase directly and immunologically, (2) show that nattokinase and/or its metabolites were detectable in human blood following ingestion of a commercial preparation, and (3) chart a pharmacokinetic dosing effect for nattokinase." | ( A pilot study on the serum pharmacokinetics of nattokinase in humans following a single, oral, daily dose. Ero, MP; Harvey, NR; Lewis, BH; Mihailovski, T; Ng, CM, ) | 0.67 |
" A pharmacokinetic pattern was observed for nattokinase between baseline and 48 h postdose." | ( A pilot study on the serum pharmacokinetics of nattokinase in humans following a single, oral, daily dose. Ero, MP; Harvey, NR; Lewis, BH; Mihailovski, T; Ng, CM, ) | 0.65 |
" The results further suggest that a larger, more extensive, pharmacokinetic study of nattokinase is warranted." | ( A pilot study on the serum pharmacokinetics of nattokinase in humans following a single, oral, daily dose. Ero, MP; Harvey, NR; Lewis, BH; Mihailovski, T; Ng, CM, ) | 0.61 |
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" Little is known regarding the pharmacokinetic and pharmacodynamic properties of this enzyme, and the bioavailability of nattokinase is currently unknown." | ( A pilot study on the serum pharmacokinetics of nattokinase in humans following a single, oral, daily dose. Ero, MP; Harvey, NR; Lewis, BH; Mihailovski, T; Ng, CM, ) | 0.6 |
" Moreover, the highest bioavailability was achieved by W/O/W emulsions coated with 1:3 ratio complex at 80." | ( The structural and functional properties of soybean protein-polyglutamic acid complex effected the stability of W/O/W emulsion encapsulated Nattokinase. Fan, B; Gao, Y; Hou, L; Hu, M; Li, D; Li, S; Tian, Z; Wang, F; Wen, W, 2023) | 1.11 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
"This study intended to (1) detect nattokinase directly and immunologically, (2) show that nattokinase and/or its metabolites were detectable in human blood following ingestion of a commercial preparation, and (3) chart a pharmacokinetic dosing effect for nattokinase." | ( A pilot study on the serum pharmacokinetics of nattokinase in humans following a single, oral, daily dose. Ero, MP; Harvey, NR; Lewis, BH; Mihailovski, T; Ng, CM, ) | 0.67 |
Research
Studies (153)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (0.65) | 18.7374 |
1990's | 4 (2.61) | 18.2507 |
2000's | 38 (24.84) | 29.6817 |
2010's | 69 (45.10) | 24.3611 |
2020's | 41 (26.80) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 60.43
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (60.43) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 9 (5.70%) | 5.53% |
Reviews | 13 (8.23%) | 6.00% |
Case Studies | 2 (1.27%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 134 (84.81%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |